Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced on September 23, 2024, that its Board of Directors granted Catherine Owen Adams, the new Chief Executive Officer, a one-time sign-on equity award. The award consists of:
1. 353,261 options to purchase Acadia's common stock at $16.29 per share, vesting 25% on the first anniversary and monthly over the next three years.
2. 160,763 performance stock units, earnable based on relative total shareholder return metrics over three years (0-150% of target).
These Inducement Awards were approved under Acadia's 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). Acadia is known for developing the first FDA-approved drugs for Parkinson's disease psychosis and Rett syndrome, with ongoing clinical-stage efforts in Prader-Willi syndrome and Alzheimer's disease psychosis.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) ha annunciato il 23 settembre 2024 che il suo Consiglio di Amministrazione ha concesso a Catherine Owen Adams, il nuovo Amministratore Delegato, un premio azionario una tantum per l'assunzione. Il premio consiste in:
1. 353.261 opzioni per acquistare azioni ordinarie di Acadia a $16,29 per azione, con il 25% che matura al primo anniversario e mensilmente nei successivi tre anni.
2. 160.763 unità azionarie legate al rendimento, guadagnabili in base a metriche di ritorno totale per gli azionisti relative nel corso di tre anni (0-150% dell'obiettivo).
Questi Premi di Induzione sono stati approvati nell'ambito del Piano di Induzione del 2024 di Acadia, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4). Acadia è conosciuta per aver sviluppato i primi farmaci approvati dalla FDA per la psicosi della malattia di Parkinson e per la sindrome di Rett, con sforzi clinici in corso nella sindrome di Prader-Willi e nella psicosi associata alla malattia di Alzheimer.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) anunció el 23 de septiembre de 2024 que su Junta Directiva otorgó a Catherine Owen Adams, la nueva Directora Ejecutiva, un premio de acciones único por contratación. El premio consiste en:
1. 353.261 opciones para comprar acciones ordinarias de Acadia a $16.29 por acción, con un 25% que se devenga en el primer aniversario y mensualmente durante los siguientes tres años.
2. 160.763 unidades de acciones de desempeño, que se pueden ganar según las métricas de retorno total para los accionistas en tres años (0-150% del objetivo).
Estos Premios de Inducción fueron aprobados bajo el Plan de Inducción 2024 de Acadia de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4). Acadia es conocida por desarrollar los primeros medicamentos aprobados por la FDA para la psicosis del párkinson y la síndrome de Rett, con esfuerzos clínicos en curso en la síndrome de Prader-Willi y la psicosis asociada a la enfermedad de Alzheimer.
아카디아 파마수티컬스(주) (Nasdaq: ACAD)는 2024년 9월 23일 이사회의 결의를 통해 Catherine Owen Adams 신임 최고경영자에게 일회성 주식 보상 패키지를 수여하기로 했다고 발표했습니다. 보상 패키지는 다음과 같습니다:
1. 아카디아의 보통주를 주당 $16.29에 구매할 수 있는 353,261개의 옵션, 첫 해 기념일에 25%가 확정되며 이후 3년 동안 매달 확정됩니다.
2. 3년 동안의 총 주주 수익을 기준으로 획득할 수 있는 160,763개의 성과 주식 단위(목표의 0-150%).
이 유인 보상은 Nasdaq 상장 규정 5635(c)(4)에 따라 아카디아의 2024 유인 계획 하에 승인되었습니다. 아카디아는 파킨슨병의 정신병 및 레트 증후군에 대한 최초의 FDA 승인 약물을 개발한 것으로 알려져 있으며, 현재 프라더-윌리 증후군 및 알츠하이머병의 정신병에 대한 임상 단계 노력을 진행하고 있습니다.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) a annoncé le 23 septembre 2024 que son Conseil d'Administration a accordé à Catherine Owen Adams, la nouvelle Directrice Générale, une prime en actions unique à la signature. La prime se compose de :
1. 353.261 options d’achat d’actions ordinaires d’Acadia à 16,29 $ par action, vesting 25% à la première date anniversaire et mensuellement pendant les trois années suivantes.
2. 160.763 unités d'actions de performance, gagnables sur la base de métriques de rendement total des actionnaires sur trois ans (0-150% de l'objectif).
Ces Prix d'Induction ont été approuvés dans le cadre du Plan d'Induction 2024 d'Acadia, conformément à la Règle de Cotation Nasdaq 5635(c)(4). Acadia est connue pour avoir développé les premiers médicaments approuvés par la FDA pour la psychose de la maladie de Parkinson et le syndrome de Rett, avec des efforts cliniques en cours dans le cadre du syndrome de Prader-Willi et de la psychose de la maladie d'Alzheimer.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) gab am 23. September 2024 bekannt, dass der Vorstand Catherine Owen Adams, der neuen Geschäftsführerin, eine einmalige Aktienprämie gewährt hat. Die Prämie besteht aus:
1. 353.261 Optionen zum Kauf von Acadia Stammaktien zu je 16,29 $ pro Aktie, wobei 25% am ersten Jahrestag und monatlich über die nächsten drei Jahre fällig werden.
2. 160.763 Performance-Aktieneinheiten, die basierend auf den Relativen Gesamtaktionärsrenditen über einen Zeitraum von drei Jahren (0-150% des Ziels) verdient werden können.
Diese Induktionsprämien wurden im Rahmen des Aktionsplans 2024 von Acadia gemäß der Nasdaq-Übersichtsregel 5635(c)(4) genehmigt. Acadia ist bekannt für die Entwicklung der ersten von der FDA zugelassenen Medikamente gegen die Psychose bei Parkinson-Krankheit und Rett-Syndrom, mit laufenden klinischen Bemühungen bei Prader-Willi-Syndrom und der Psychose bei Alzheimer-Krankheit.
- Appointment of a new Chief Executive Officer, Catherine Owen Adams
- Granting of performance-based equity awards to align CEO interests with shareholders
- Continued focus on neuroscience breakthroughs and FDA-approved drugs for rare conditions
- Potential shareholder dilution due to the issuance of new stock options and performance stock units
Insights
The appointment of Catherine Owen Adams as Acadia Pharmaceuticals' new CEO, accompanied by a substantial equity package, signals a significant leadership transition. The inducement grant, comprising 353,261 stock options and 160,763 performance stock units (PSUs), is structured to align the CEO's interests with shareholders over the long term.
The stock options, priced at
This compensation package, while substantial, is not uncommon for attracting top talent in the biotech sector. The focus on long-term vesting and performance metrics suggests the board is prioritizing sustained growth and shareholder value creation. However, investors should monitor how this aligns with Acadia's financial performance and pipeline progress in the coming years.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240926821104/en/
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com
Source: Acadia Pharmaceuticals Inc.
FAQ
What equity awards did Acadia Pharmaceuticals (ACAD) grant to its new CEO on September 23, 2024?
How do the stock options granted by Acadia Pharmaceuticals (ACAD) to its new CEO vest?
What are the performance metrics for the stock units granted by Acadia Pharmaceuticals (ACAD) to its new CEO?
Under what plan were the Inducement Awards granted by Acadia Pharmaceuticals (ACAD)?
